These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 27168021)

  • 1. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
    Lievense LA; Bezemer K; Cornelissen R; Kaijen-Lambers ME; Hegmans JP; Aerts JG
    Lung Cancer; 2017 May; 107():36-40. PubMed ID: 27168021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
    Cornelissen R; Lievense LA; Robertus JL; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
    Lung Cancer; 2015 Jun; 88(3):332-7. PubMed ID: 25843042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression.
    Lievense LA; Cornelissen R; Bezemer K; Kaijen-Lambers ME; Hegmans JP; Aerts JG
    J Thorac Oncol; 2016 Oct; 11(10):1755-64. PubMed ID: 27418106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
    Minnema-Luiting J; Vroman H; Aerts J; Cornelissen R
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29601534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
    Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
    J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
    Scherpereel A; Grigoriu BD; Noppen M; Gey T; Chahine B; Baldacci S; Trauet J; Copin MC; Dessaint JP; Porte H; Labalette M
    BMC Cancer; 2013 Jul; 13():324. PubMed ID: 23816056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
    Ceresoli GL; Bonomi M; Sauta MG
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.
    DeLong P; Carroll RG; Henry AC; Tanaka T; Ahmad S; Leibowitz MS; Sterman DH; June CH; Albelda SM; Vonderheide RH
    Cancer Biol Ther; 2005 Mar; 4(3):342-6. PubMed ID: 15846066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
    Hegmans JP; Hemmes A; Hammad H; Boon L; Hoogsteden HC; Lambrecht BN
    Eur Respir J; 2006 Jun; 27(6):1086-95. PubMed ID: 16540497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
    Van den Bossche J; De Laere M; Deschepper K; Germonpré P; Valcke Y; Lamont J; Stein B; Van Camp K; Germonpré C; Nijs G; Roelant E; Anguille S; Lion E; Berneman Z
    PLoS One; 2024; 19(7):e0307204. PubMed ID: 39008481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
    Wong RM; Ianculescu I; Sharma S; Gage DL; Olevsky OM; Kotova S; Kostic MN; Grundfest WS; Hou D; Cameron RB
    Am J Respir Cell Mol Biol; 2014 May; 50(5):870-5. PubMed ID: 24450537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Narrative Review-Management of Malignant Pleural Effusion Related to Malignant Pleural Mesothelioma.
    Qureshi M; Thapa B; Muruganandan S
    Heart Lung Circ; 2023 May; 32(5):587-595. PubMed ID: 36925448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
    Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T
    J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages.
    Chéné AL; d'Almeida S; Blondy T; Tabiasco J; Deshayes S; Fonteneau JF; Cellerin L; Delneste Y; Grégoire M; Blanquart C
    J Thorac Oncol; 2016 Oct; 11(10):1765-73. PubMed ID: 27418105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.